Sangamo Therapeutics recently filed a notice with the U.S. SEC describing a data security breach.
Med Ad News Announces Finalists for the 2018 Manny Awards and Names Sharon Callahan, CEO of TBWA\WorldHealth, as Industry Person of the Year
Med Ad News announced the nominees for the 29th Annual Manny Awards and named TBWA\WorldHealth CEO Sharon Callahan as the Industry Person of the Year.
The names of the tools may be changing, but the goal for brand managers remains the same in 2018: getting as close as possible to real patients and their needs.
Executives from 2017 Manny Award winners/finalists and other healthcare communications agencies participated in this Q&A forum of industry topics.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
Two have been around in the pharmaceutical industry for a long time, and one is a relative newcomer. In considering this year’s pharma innovators to profile, the results of their accomplishments, not how long they have been around, steered the direction of this feature. Donna Murphy, global CEO of the recently formed agency network Havas Health & You; Abraham Gutman, president and CEO of AG Mednet; and C. David Nicholson, executive VP and chief R&D officer of Allergan, are being saluted for bringing new innovations to the fields of pharmaceutical advertising, clinical trial imaging and R&D, and their accomplishments are expected to echo into the future.
Johnson & Johnson reported a strong first-quarter 2018 with $20 billion in sales that was fueled by significant growth in the company’s pharmaceuticals business.
Paris-based Sanofi agreed to sell the company’s generics division Zentiva to the private equity firm Advent International for 1.9 billion euros ($2.4 billion). The deal is expected to wrap by year-end 2018.
Shire, a global biotechnology company focused on rare diseases, sold its oncology business to France’s Servier for $2.4 billion.
Boehringer Ingelheim and Eli Lilly announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes.
Rigel Pharmaceuticals’ website erroneously claimed the company’s drug candidate Tavalisse gained approval from the U.S. FDA.
Bristol-Myers Squibb and the Harvard Fibrosis Network, part of the Harvard Stem Cell Institute, launched a collaboration to discover and develop new therapies for fibrotic diseases.
GlaxoSmithKline is divesting its rare disease gene therapy drugs to private biotech company Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker’s pharmaceuticals portfolio.
A federal judge pushing for a settlement in lawsuits seeking to hold drug companies responsible for their roles in the U.S. opioid epidemic set an aggressive schedule that would have the first trial take place in March 2019.
Drugstore chain CVS Health Corp. launched a new tool that will allow pharmacies help customers tackle the soaring cost of drugs by comparing prices of medicines.
Alex ion Pharmaceuticals agreed to buy Sweden’s Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million).
Illumina is teaming up with Loxo Oncology to develop and commercialize a multi-gene panel for broad cancer profiling.
Mylan NV will buy global marketing rights to an experimental multiple sclerosis treatment from Israel’s Mapi Pharma, aiming to strengthen its position in the market for MS drugs and counter falling sales of the emergency allergy shot EpiPen.
Pfizer signed a 20-year lease for the company’s new global headquarters at The Spiral, an office tower being built by Tishman Speyer at 66 Hudson Boulevard at Hudson Yards of Manhattan.
Swiss pharma giant Roche has completed the acquisition of Flatiron Health and secured a big win with the United Kingdom’s healthcare provider for the lung cancer drug Tecentriq.
Swiss-based Novartis struck a deal to acquire Bannockburn, Illinois-based AveXis for $8.7 billion. Novartis will pay $218 per share.
Ionis Pharmaceuticals Inc. said on Monday a licensing deal for the company’s fatty liver disease treatment with AstraZeneca Plc could fetch up to $300 million in milestone payments.
Health officials in New Jersey are investigating an E. coli outbreak in four counties that left at least eight people hospitalized.
Johnson & Johnson suffered the company’s first trial loss in a lawsuit claiming its talc-based products including Johnson’s Baby Powder contain cancer-causing asbestos, with a New Jersey jury ordering J&J and another company to pay $37 million in damages.
Medicare will pay hospitals close to its standard mark-up rate for administering the cell therapy Yescarta for cancer outpatients, who will have a co-payment of nearly $80,000, according to the Centers for Medicare & Medicaid Services (CMS).